arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

Neurogene Inc.

NGNE Health Care Biotechnology: Pharmaceutical Preparations
$23.55
▼ -9.7% Today
as of Oct 23, 16:50 ET
Last 30 days -33.12% Sep 14 → Oct 23
$20.47 $24.43 $28.38 $32.34 $36.30 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$24.11
High
$24.11
Low
$23.07
Volume
$124,509
Avg Vol
$218,272
Mkt Cap
$531M
P/E (TTM)
—
Beta
—
52w High
$43.66
52w Low
$15.93
Div Yield
—
Shares Out
$16M

Recent Press Releases & News last 60 days · 5 items

Oct 20 · 11:30 PR Business Wire
Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress
Oct 8 · 11:29 MT Newswires
JPMorgan Initiates Neurogene at Overweight With $60 Price Target
Oct 5 · 20:01 PR Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
▸ Show all 5 press releases & news Free account →

NGNE earnings at a glance

The options market is pricing a move of about ±20.8% after the report, a range of roughly $18.66 to $28.44 from today's $23.55. Over its last 2 reports the stock rose the next day 1 time and fell 1, moving ±2.0% on average; after the most recent report on May 12, 2026 it moved +2.1%. That means options currently expect more movement than NGNE has typically delivered. NGNE beat the consensus EPS estimate in 2 of its last 4 reported quarters. Implied volatility is currently 176%. The share price of $23.55 sits in the middle of its 52-week range.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$16
$44
27% of range
Avg surprise (last 4)
+6.1%
Avg reaction (last 2)
+0.2%
50% positive
Latest IV / EM
176%
EM ±20.8% · $25 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-32.67$-24.57$-16.46$-8.36$-0.26 Actual $-0.26Actual $-26.68Actual $-32.67Actual $-1.00Actual $-1.09Actual $-1.19Actual $-1.08Est $-1.05Actual $-1.05Est $-1.15Actual $-0.99Est $-1.26Actual $-1.39Est $-1.35Actual $-1.53 MarJunSepMarJunSepMar/2025Jun/2025Sep/2025Mar/2026Jun
Revenue vs Net Income Revenue Net income
$-34M$-31M$-28M$-25M$-21M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Jun 30, 2026Jun 2026 $-1.53 — — — — financials
Tue May 12, 2026Mar/2026 $-1.39 $-1.35 -3.0% -28.7% +2.1% earnings
Thu Nov 13, 2025Sep/2025 $-0.99 $-1.26 +21.4% — — earnings
Mon Aug 11, 2025Jun/2025 $-1.05 $-1.15 +8.7% — — earnings
Fri May 9, 2025Mar/2025 $-1.08 $-1.05 -2.9% — -1.8% earnings
Mon Sep 30, 2024Sep 2024 $-1.19 — — — — financials
Sun Jun 30, 2024Jun 2024 $-1.09 — — — — financials
Sun Mar 31, 2024Mar 2024 $-1.00 — — — — financials
Sat Sep 30, 2023Sep 2023 $-32.67 — — — — financials
Fri Jun 30, 2023Jun 2023 $-26.68 — — — — financials
Fri Mar 31, 2023Mar 2023 $-0.26 — — — — financials

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue———$0$0——$0
Cost of revenue————————
Gross profit————————
Operating income$-37M$-33M—$-24M$-26M$-26M—$-22M
Net income$-34M$-31M—$-21M$-22M$-23M—$-20M
EPS (diluted)$-1.53$-1.39—$-0.99$-1.05$-1.08—$-1.19

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$112M$124M$104M$71M$59M$71M$137M$67M
Inventory————————
Total current assets$229M$247M$272M$271M$279M$296M$316M$144M
Total assets$244M$263M$289M$288M$297M$315M$336M$164M
Long-term debt————————
Total liabilities$27M$25M$24M$22M$24M$24M$25M$27M
Total equity$217M$238M$265M$266M$273M$292M$310M$137M

Implied volatility — last 90 days

68%168%267%366%465% Jun 07 — IV 213% · EM ±29.4%Jun 08 — IV 226% · EM ±29.9%Jun 09 — IV 179% · EM ±22.5%Jun 10 — IV 209% · EM ±24.6%Jun 11 — IV 169% · EM ±18.6%Jun 12 — IV 181% · EM ±18.6%Jun 15 — IV 250% · EM ±18.1%Jun 16 — IV 303% · EM ±17.9%Jun 17 — IV 371% · EM ±15.5%Jun 19 — IV 118% · EM ±26.2%Jun 22 — IV 128% · EM ±26.8%Jun 23 — IV 143% · EM ±29.2%Jun 24 — IV 145% · EM ±29.1%Jun 25 — IV 136% · EM ±26.6%Jun 26 — IV 136% · EM ±26.0%Jun 29 — IV 130% · EM ±23.0%Jun 30 — IV 130% · EM ±22.4%Jul 01 — IV 122% · EM ±20.4%Jul 02 — IV 97% · EM ±15.7%Jul 03 — IV 100% · EM ±15.7%Jul 06 — IV 128% · EM ±17.8%Jul 07 — IV 106% · EM ±14.0%Jul 08 — IV 120% · EM ±15.0%Jul 09 — IV 110% · EM ±13.0%Jul 10 — IV 93% · EM ±10.3%Jul 13 — IV 172% · EM ±14.4%Jul 14 — IV 191% · EM ±13.8%Jul 16 — IV 394% · EM ±16.4%Jul 20 — IV 107% · EM ±25.3%Jul 21 — IV 88% · EM ±20.4%Jul 22 — IV 93% · EM ±21.2%Jul 23 — IV 96% · EM ±21.6%Jul 24 — IV 106% · EM ±23.4%Jul 27 — IV 110% · EM ±23.0%Jul 28 — IV 115% · EM ±23.6%Jul 29 — IV 116% · EM ±23.2%Jul 30 — IV 111% · EM ±21.7%Jul 31 — IV 117% · EM ±22.4%Aug 03 — IV 124% · EM ±22.1%Aug 04 — IV 114% · EM ±19.7%Aug 05 — IV 101% · EM ±16.9%Aug 06 — IV 103% · EM ±16.7%Aug 07 — IV 100% · EM ±15.6%Aug 10 — IV 130% · EM ±18.1%Aug 11 — IV 113% · EM ±14.9%Aug 12 — IV 138% · EM ±17.3%Aug 13 — IV 116% · EM ±13.8%Aug 14 — IV 154% · EM ±17.0%Aug 17 — IV 250% · EM ±20.9%Aug 18 — IV 194% · EM ±14.0%Aug 19 — IV 213% · EM ±12.6%Aug 20 — IV 340% · EM ±14.2%Aug 24 — IV 91% · EM ±19.0%Aug 25 — IV 89% · EM ±18.2%Aug 26 — IV 89% · EM ±17.8%Aug 27 — IV 93% · EM ±18.2%Aug 28 — IV 73% · EM ±14.0%Aug 31 — IV 69% · EM ±12.2%Sep 01 — IV 127% · EM ±21.8%Sep 02 — IV 80% · EM ±13.4%Sep 03 — IV 123% · EM ±19.9%Sep 04 — IV 119% · EM ±18.7%Sep 07 — IV 135% · EM ±18.7%Sep 08 — IV 139% · EM ±18.4%Sep 09 — IV 126% · EM ±15.8%Sep 10 — IV 137% · EM ±16.2%Sep 11 — IV 139% · EM ±15.4%Sep 14 — IV 170% · EM ±14.2%Sep 15 — IV 205% · EM ±14.8%Sep 17 — IV 465% · EM ±19.4%Sep 21 — IV 93% · EM ±19.4%Sep 22 — IV 87% · EM ±17.9%Sep 23 — IV 75% · EM ±15.0%Sep 24 — IV 77% · EM ±15.0%Sep 25 — IV 108% · EM ±20.8%Sep 28 — IV 134% · EM ±23.7%Sep 29 — IV 124% · EM ±21.3%Sep 30 — IV 116% · EM ±19.4%Oct 01 — IV 93% · EM ±15.0%Oct 02 — IV 137% · EM ±21.4%Oct 06 — IV 149% · EM ±19.7%Oct 08 — IV 176% · EM ±20.8%

Sector peers

CAPR
Capricor Therapeutics, Inc.
$520M $5.93+0.8%
OCS
Oculis Holding AG
$508M $7.90+0.4%
CTMX
CytomX Therapeutics, Inc.
$556M $2.32-3.3%
PBYI
Puma Biotechnology Inc
$506M $11.02+1.1%
CBIO
Crescent Biopharma, Inc.
$501M $12.82-2.7%
ACRS
Aclaris Therapeutics, Inc.
$500M $3.75-1.6%

NGNE earnings FAQ

What is NGNE's expected move for earnings?

Options currently price a move of about ±20.8%, or $4.89 per share either way from $23.55.

How does NGNE stock usually react to earnings?

Across the last 2 reports the average next-day move was ±2.0%, up 1 times and down 1 times.

What is NGNE's implied volatility?

NGNE's at-the-money implied volatility is about 176% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in